Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.45 |
| ▸ | XPO1 | O14980 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29683992 | 1.00 | SLC40A1 (0.45) | SLC40A1XPO1ARCYP3A4TSHR | |
| SCHEMBL13906830 | 0.82 | NCF1 (0.59) | LMNAPDE10AMCHR1BACE1PLAU | |
| SCHEMBL30035233 | 0.82 | NCF1 (0.59) | LMNAPDE10AMCHR1BACE1PLAU | |
| SCHEMBL29533844 | 0.79 | CCR1 (0.43) | SLC40A1CYP3A4TSHRLMNAMCHR1 | |
| SCHEMBL557084 | 0.79 | CCR1 (0.43) | SLC40A1CYP3A4TSHRLMNAMCHR1 | |
| SCHEMBL23548885 | 0.77 | XPO1 (0.41) | SLC40A1XPO1ARCYP3A4TSHR | |
| SCHEMBL3850693 | 0.77 | XPO1 (0.41) | XPO1ARCYP3A4TSHRCYP1A2 | |
| SCHEMBL1030675 | 0.77 | BACE1 (0.64) | SLC40A1ARCYP3A4TSHRLMNA | |
| SCHEMBL1967396 | 0.77 | SLC40A1 (0.42) | SLC40A1ARCYP3A4TSHRLMNA | |
| SCHEMBL934781 | 0.77 | KMT2A (0.42) | XPO1ARCYP3A4TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4198022-A1 | PREPARATION OF COMPOUNDS USEFUL FOR TREATING AIDS | ABIVAX (FR) | 2023-06-21 | — | — | EP | claimed |
| US-10975063-B2 | Compound, and production method thereof, and methods of treatment using the compound | ABIVAX (FR) | 2021-04-13 | — | — | US | claimed |
| US-20190322656-A1 | COMPOUND, AND PRODUCTION METHOD THEREOF, AND METHODS OF TREATMENT USING THE COMPOUND | ABIVAX (FR) | 2019-10-24 | — | — | US | claimed |
| EP-3429998-B3 | PROCESS FOR PREPARING QUINOLIN-2-YL-PHENYLAMINE DERIVATIVES AND THEIR SALTS | ABIVAX (FR) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035348-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2026-02-05 | — | — | US | disclosed |
| EP-4363415-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2025-12-10 | — | — | EP | disclosed |
| US-12479802-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ABIVAX (FR) | 2025-11-25 | — | — | US | disclosed |
| EP-4635942-A1 | QUINOLINE DERIVATIVE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Carephar Pharmaceutical Co., Ltd (CN) | 2025-10-22 | — | — | EP | disclosed |
| EP-4624469-A1 | QUINOLINE AMINE COMPOUND CRYSTAL FORM AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-20250100971-A1 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | ABIVAX (FR) | 2025-03-27 | — | — | US | disclosed |
| US-12202804-B2 | In vitro or ex vivo methods for screening a quinoline derivative | ABIVAX (FR) | 2025-01-21 | — | — | US | disclosed |
| WO-2006004865-A1 | 2-SUBSTITUTED QUINOLINE COMPOUNDS AND THEIR USES AS INHIBITORS OF THE IGE RECEPTOR SIGNALING CASCADE | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| CN-1402721-A | Novel benzimidazole derivatives as antiproliferative agents | PFIZER PROD INC (US) | 2003-03-12 | — | — | CN | disclosed |
| EP-1235825-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-0317188-B1 | Heteroaromatic enamide derivatives and their use as pesticides | ROUSSEL UCLAF (FR) | 1995-09-27 | — | — | EP | disclosed |
| US-5114940-A | Insecticides or anthelmintics from fused ring heterocycles containing amides or thioamides | ROUSSEL-UCLAF (FR) | 1992-05-19 | — | — | US | disclosed |
| EP-0317188-A2 | Heteroaromatic enamide derivatives and their use as pesticides | ROUSSEL UCLAF (FR) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | SLC40A1 2519/4885XPO1 1440/4885AR 2933/4885 |
| US-20260035348-A1 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | SARS1, NDUFC2, CLIC1 | SLC40A1 887/4885XPO1 3609/4885AR 1976/4885 |
| US-20190322656-A1 | COMPOUND, AND PRODUCTION METHOD THEREOF, AND METHODS OF TREATMENT USING THE COMPOUND | CXCL8, FURIN, ABL1 | SLC40A1 1577/4885XPO1 200/4885AR 3969/4885 |
| US-12202804-B2 | In vitro or ex vivo methods for screening a quinoline derivative | CD14, MYADM, SYNCRIP | SLC40A1 654/4885XPO1 1434/4885AR 4801/4885 |
| US-20250100971-A1 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | SSB, SYVN1, TLR7 | SLC40A1 1167/4885XPO1 559/4885AR 4693/4885 |
| US-12479802-B2 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | ORC3, NSUN3, POLR2H | SLC40A1 3842/4885XPO1 2079/4885AR 2947/4885 |
| US-10975063-B2 | Compound, and production method thereof, and methods of treatment using the compound | CXCL8, FURIN, ABL1 | SLC40A1 1577/4885XPO1 200/4885AR 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.